Skip to main content
Top
Published in: Digestive Diseases and Sciences 8/2020

01-08-2020 | Pancreatic Cyst | Editorial

Next-Generation Sequencing (NGS) in the Prediction of Pancreatic Malignancy: Does Cell Free Mean Error Free?

Author: V. V. Ravikanth

Published in: Digestive Diseases and Sciences | Issue 8/2020

Login to get access

Excerpt

The prevalence of pancreatic cysts incidentally detected in the general population is reportedly high (~ 49.1%) with their number and size increasing with age [1]. Pancreatic cysts commonly encountered in clinical practice include serous cystadenomas (SCAs), mucinous cystic neoplasms (MCNs), and intraductal papillary mucinous neoplasm (IPMNs). The management of the pancreatic cysts usually depends on their type; SCAs with a low malignant potential require minimal or no surveillance in the absence of symptoms. Surgical resection is recommended for low-grade neoplasms including solid-pseudopapillary neoplasms (SPN). Although follow-up is recommended by a few groups for asymptomatic MCNs, surgeons favor resection since these cysts have malignant potential, requiring long periods of close surveillance. Surgery is recommended for IPMNs involving the main pancreatic duct due to a greater risk of malignant transformation. In contrast, there is a much lower risk of malignancy in branch duct-type IPMNs where there is no involvement of the main duct; close surveillance is usually recommended, with surgery advised only in the presence of certain high-risk criteria [2]. …
Literature
1.
go back to reference Kromrey ML, Bülow R, Hübner J, et al. Prospective study on the incidence, prevalence and 5-year pancreatic-related mortality of pancreatic cysts in a population-based study. Gut. 2018;67:138–145.CrossRef Kromrey ML, Bülow R, Hübner J, et al. Prospective study on the incidence, prevalence and 5-year pancreatic-related mortality of pancreatic cysts in a population-based study. Gut. 2018;67:138–145.CrossRef
2.
go back to reference Ngamruengphong S, Lennon AM. Analysis of pancreatic cyst fluid. Surg Pathol Clin. 2016;9:677–684.CrossRef Ngamruengphong S, Lennon AM. Analysis of pancreatic cyst fluid. Surg Pathol Clin. 2016;9:677–684.CrossRef
3.
go back to reference Brugge WR, Lewandrowski K, Lee-Lewandrowski E, et al. Diagnosis of pancreatic cystic neoplasms: a report of the cooperative pancreatic cyst study. Gastroenterology. 2004;126:1330–1336.CrossRef Brugge WR, Lewandrowski K, Lee-Lewandrowski E, et al. Diagnosis of pancreatic cystic neoplasms: a report of the cooperative pancreatic cyst study. Gastroenterology. 2004;126:1330–1336.CrossRef
5.
go back to reference Kornberg RD, Lorch Y. Twenty-five years of the nucleosome, fundamental particle of the eukaryote chromosome. Cell. 1999;98:285–294.CrossRef Kornberg RD, Lorch Y. Twenty-five years of the nucleosome, fundamental particle of the eukaryote chromosome. Cell. 1999;98:285–294.CrossRef
6.
go back to reference Diehl F, Li M, Dressman D, et al. Detection and quantification of mutations in the plasma of patients with colorectal tumours. Proc Natl Acad Sci USA. 2005;102:16368–16373.CrossRef Diehl F, Li M, Dressman D, et al. Detection and quantification of mutations in the plasma of patients with colorectal tumours. Proc Natl Acad Sci USA. 2005;102:16368–16373.CrossRef
7.
go back to reference Gerstung M, Jolly C, Leshchiner I, Dentro S, et al. The evolutionary history of 2,658 cancers. Nature. 2020;578:122–128.CrossRef Gerstung M, Jolly C, Leshchiner I, Dentro S, et al. The evolutionary history of 2,658 cancers. Nature. 2020;578:122–128.CrossRef
8.
go back to reference Volik S, Alcaide M, Morin RD, et al. Cell-free DNA (cfDNA): clinical significance and utility in cancer shaped by emerging technologies. Mol Cancer Res. 2016;14:898–908.CrossRef Volik S, Alcaide M, Morin RD, et al. Cell-free DNA (cfDNA): clinical significance and utility in cancer shaped by emerging technologies. Mol Cancer Res. 2016;14:898–908.CrossRef
9.
go back to reference Gundry M, Vijg J. Direct mutation analysis by high-throughput sequencing: from germline to low-abundant, somatic variants. Mutat Res. 2012;729:1–15.CrossRef Gundry M, Vijg J. Direct mutation analysis by high-throughput sequencing: from germline to low-abundant, somatic variants. Mutat Res. 2012;729:1–15.CrossRef
Metadata
Title
Next-Generation Sequencing (NGS) in the Prediction of Pancreatic Malignancy: Does Cell Free Mean Error Free?
Author
V. V. Ravikanth
Publication date
01-08-2020
Publisher
Springer US
Keyword
Pancreatic Cyst
Published in
Digestive Diseases and Sciences / Issue 8/2020
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-020-06209-2

Other articles of this Issue 8/2020

Digestive Diseases and Sciences 8/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine